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Summary Recombinant interleukin-2 (rIL-2) therapy has been shown to be of value in the treatment of
some cases of melanoma and renal cell carinoma. However its use can be limited by severe systemic toxicity.
Targeting rIL-2 to the tumour should improve the anti-tumour immune response and decrease the systemic
toxicity. With this aim we have employed recombinant DNA techniques to construct a single chain antibody
interleukin-2 fusion protein (SCA-IL-2).
The protein used in this model system comprises the variable domains of the anti-lysozyme antibody D1.3
fused to human IL-2. It has been expressed by secretion from Escherichia coli and the purified product
possesses antigen binding specificity and retains the immunostimulatory activities of rIL-2.
This approach can be taken to generate SCA-IL-2 proteins that bind to appropriate cellular antigens. In vivo
administration of a tumour binding SCA-IL-2 should result in a localised high concentration of IL-2 in
tumour tissues, maximising the anti-tumour immune response, whilst keeping systemic side effects to a
minimum.
Interleukin-2 (IL-2) is a 15 kDa cytokine produced by T
helper cells that stimulates cytotoxic T lymphocytes and NK
cells (Gillis et al., 1978). Bacterially produced recombinant
IL-2 has been used clinically in the treatment of melanoma
and renal cell carcinoma to stimulate cancer patients' im-
mune systems (Rosenberg et al., 1989). Recent pre-clinical
studies indicate that achieving a prolonged high dose of IL-2
in the tumour can result in the induction of a long lasting
anti-tumour response leading to the rejection of an otherwise
lethal tumour (Fearon et al., 1990). However the in vivo
efficacy is limited by difficulties in maintaining prolonged
high doses in the tumour and by the severe systemic toxicity
associated with high dose IL-2 therapy (Rosenberg et al.,
1989).
To achieve a selective and prolonged concentration of IL-2
in the tumour it is an attractive idea to target it there via an
antibody delivery system. IL-2 has been successfully incor-
porated into a number of fusion proteins. Fusion proteins
consisting of IL-2 linked to bacterial toxins have been pro-
duced in bacteria and have been demonstrated to be toxic to
IL-2 receptor bearing cells (Lorderboum-Galski et al., 1988;
Williams et al., 1987). With the aim of concentrating IL-2
activity in the tumour, two different antibody-IL-2 fusion
proteins have already been described. A Fab'-IL-2 fusion
protein, whilst only partially retaining IL-2 activity, has been
shown to increase the T-cell mediated killing of antigen-
bearing tumour cells in vitro (Fell et al., 1991). A larger
IgG-IL-2 fusion protein appears to retain full IL-2 activity
and is likewise able to increase effector cell mediated killing
in vitro (Gillies et al., 1992). There are potential problems
with these molecules in that they are produced in expensive
mammalian expression systems and that their large size may
result in poor tumour penetrance and prolonged blood
residues in vivo. A smaller antibody-IL-2 fusion protein based
on a bacterially produced antibody fragment may give
economic and therapeutic advantages.
As a delivery system the smaller single chain antibody
(SCA), comprising linked variable heavy (VH) and variable
light (VL) chain antibody domains shows great promise (Hus-
ton et al., 1988). Where tested SCAs demonstrate good tissue
penetration (Yokota et al., 1992), rapid renal clearance of
non-localised protein and potentially low immunogenicity
(Colcher et al., 1990). Recent advances with in vitro selection
should allow the rapid and economic production of SCA of
any required specificity (Clackson et al., 1991; Marks et al.,
1991). In this preliminary investigation the feasability of
producing a functional SCA-IL-2 was tested using the anti-
lysozyme SCA D1.3. The advantages of using this antibody
are that it is well characterised, it is secreted well and it is
easy to detect by Elisa and to affinity purify. As we employed
a SCA unsuitable for cytotoxicity assays we are not able to
add to the already strong evidence for the benefits of concen-
trating IL-2 in tumours. However we are able to demonstrate
for the first time that this fusion protein, in addition to
retaining antigen binding ability, possesses the immuno-
stimulatory actions of IL-2 when tested with lymphocytes
bearing the high affinity IL-2 receptor. Furthermore the
SCA-IL-2 fusion molecule described here retains the ability
to stimulate cells expressing low affinity IL-2 receptors as
measured by its proliferative effects on human peripheral
blood lymphocytes.
Materials and methods
Plasmid assembly
Single colonies of E.coli containing plasmid pSV-HIL2-0
(Gift of Professor W. Friers, University of Ghent) were
suspended in 500 fcl of water, boiled for 5 min and cleared by
centrifugation in a microfuge. Aliquots (10 cLI) of the super-
natant were subjected to polymerase chain reaction (PCR)
amplification according to the manufacturers instructions
(Perkin Elmer Cetus, Norwalk, USA) in the presence of
25 pmol each of oligonucleotide primers IL-2/7 and IL-2 3'.
The reaction underwent 30 cycles of denaturation (94°C,
1 min), annealing (50°C, min) and extension (72C, 1 min).
Oligonucleotide primer IL-2/7, (5'-ACCAAGCTCGAGATC-
AAACGGGAACAAAAACTCCCTACTTCAAGTTCT-3')
direct incorporation of an Xho I site and the seven carboxy-
terminal amino acids of the VL chain domain of the D1l.3
SCA plasmid (pSWsFVDI.3myc, McCafferty et al., 1990;
Gift of Dr E.S. Ward, LMB, Cambridge) fused to sequence
encoding amino acids 2-7 of human IL-2. Primer IL-2 3',
(5'-TTCTCGAATTCGAGCTGGATCCTTATTAAGTCAG-
TGTTGAGATGAT-3'), directs the incorporation of an
EcoRI site downstream of the termination codon of human
IL-2. The 440 bp amplified product was isolated from a 1.5%
agarose gel, digested with Xho I and EcoRI and ligated
between the Xho I and EcoRI sites of plasmid pSWsFVD
1.3myc to generate plasmid pSCA-IL-2/7. This plasmid bears
a chimeric gene encoding a single chain antibody-IL-2 fusion
protein (SCA-IL-2) under lac transcriptional control. Figure
1 shows plasmids used, the nucleotide sequence and the
deduced amino acid sequence at the fusion junction.
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Figure 1 Construction ofplasmid pCA-IL-2/7. Upper: amplification and modification of the IL-2 gene; middle: replacement of the
c-myc-derived portion with the modified IL-2 gene (not to scale); and lower: nucleotide and derived amino-acid sequences of the
non-transcribed strand at the junction between the segments encoding antibody domains and the IL-2 gene. Plasmids pSCA-IL-2/7
and pSWsFVDI.3myc are pUC19 derivatives. Only the sections between the HindIII and EcoRI sites of the cloning region are
shown.
Expression andpartialpurification ofSCA-IL-2 protein
Cultures (500 ml) of E.coli K12 KS476 (Stauch et al., 1989;
Gift of Professor J. Beckwith, Harvard) transformed with
plasmid pSCA-IL-2/7 were grown overnight at 37°C in
2 x TY broth supplemented with appropriate antibodies and,
to ensure growth in repressing conditions, 1% glucose. Cells
were harvested, washed twice in sterile standard phosphate
buffered saline (PBS pH 7.6) at 27°C, suspended in fresh
growth media containing appropriate antibiotics, sup-
plemented with 0.1 mM isopropyl-b-D-thiogalactopyranoside
(IPTG), and shaken for 16 h at 25°C to permit accumulation
of the fusion protein. After expression, cells were harvested,
the bacterial growth supernatant was filtered (0.22 mm filter)
and applied at room temperature to a lysozyme-Sepharose
column. After washing with PBS, bound protein was eluted
as described previously (Ward et al., 1989). Prior to use the
fusion protein was dialysed exhaustively against PBS and
stored at - 20°C.
ELISAs
For serological detection of SCA-IL-2 fusions proteins,
enzyme linked immunosorbent assays (ELISAs) were em-
ployed. Flat bottomed Dynatech Immulon 96 well plates
were coated overnight at 25C with hen egg lysozyme
(300 jigml-'), goat polyclonal anti-IL-2 antibody (501g ml-',
British Biotechnology Oxford) or other proteins (BSA, KLH,
reconstituted milk powder, or insulin at appropriate concent-
rations) applied in 50 mM bicarbonate buffer pH 9.6. Unoc-
cupied sites were blocked with a 1% solution of milk powder
in PBS for 30 min at 25°C. Bacterial supernatants, affinity
purified material or recombinant IL-2 (rIL-2, Boehringer
Mannheim, Germany) were diluted in PBS/l % milk powder
and incubated (30 min, 25°C) in appropriate wells. After
three washes in PBS, bound protein was detected with either
polyclonal anti IL-2 or DMS1 (Smith et al., 1983), a murine
monoclonal antibody that recognises the receptor binding site
of human IL-2 (Gift of Professor K.A. Smith, Dartmouth
Medical School, USA). After a further three washes, bound
antibody was detected with a species specific HRP con-
jugated antibody (DAKO, Copenhagen, Denmark). ABTS
was added to generate a colour change that was monitored at
405 nm.
Western blots
Affinity purified protein samples were electrophoresed through
15% 30:1 acrylamide: bis-acrylamide gels essentially as de-
scribed in Laemmli (Laemmli, 1970) and transferred electro-
phoretically to a nitrocellulose membrane (Towbin et al.,
1979). The membrane was blocked (30min, 25°C) in a 1%
solution of milk powder in Tris-buffered saline/0.0025%
Tween 20 (TBST). Proteins were detected by incubation (1 h,
25°C) with either rabbit anti-SCA serum (Gift of E.S. Ward)
or mouse monoclonal DMS1. After five washes in TBST,
bound first step antibody was detected with anti-rabbit or
anti-mouse AP conjugated antibody (Amersham, Bucks, UK)
and revealed by incubation with a solution of NBT and
BCIP (Promega, Madison, USA), according to the manufac-
turers recommendations.
FACS analysis
CTLL-2 cells (Gillis & Smith, 1977) deprived of IL-2 for 12 h
were seeded into Nunc 96 well plates at 105 per well in 200flI
volumes. To the cells was added either a 1:15 dilution of
fusion protein, approximating to an activity of 100 U IL-
2 ml-', an equivalent dilution of native SCA, rIL-2 at
100 U ml-' or a mixture of SCA and rIL-2. For competitive
inhibition, cells were exposed to 5000 U ml-' of rIL-2 or
pXho 1
primer IL-2n IL-2 gene
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TNF at 10pg ml-1 for 10 min prior to the addition of SCA-
IL-2 as above. After incubation, cell associated SCA epitopes
were detected by incubation with rabbit anti-SCA serum and
then the bound rabbit anti-SCA antibodies were detected
with FITC-conjugated anti-rabbit IgG (Sigma). After fixing
with 1% paraformaldehyde, cell surface fluourescence was
measured using a Becton Dickinson FACScan. Cells were
washed five times between steps with RPMI to remove
unbound material, and all incubations were for 30 min at
40C.
Bioactivity assays
CTLL-2 cells (Gillis et al., 1978), which bear the high affinity
IL-2 receptor, were maintained in RPMI media supple-
mented with 10% foetal calf serum (heat inactivated) and
10U 1- rIL-2. For assay, cells were washed in media and
deprived of IL-2 for 4 h, after which they were seeded into 96
well plates at 5 x 103 per well. Dilutions of fusion protein or
rIL-2 were added and the cultures incubated for 18 h at 37°C
in a 5% CO2 atmosphere. Then to each well 0.5glCi of
3H-thymidine (Amersham) was added. After a further 4 h
incubation cells were harvested onto glass fibre filters, dried
and the incorporated radioactivity counted. For inhibition
assays, fusion protein or rIL-2 at five times the concentration
that produced 50% maximal stimulation of CTLL-2 cells was
incubated with dilutions of goat anti-IL-2 antibody (30 min,
37°C) prior to addition to the CTLL-2 cells, for assay as
described above.
Peripheral blood lymphocytes were obtained by venepunc-
ture from healthy donors and prepared by differential centri-
fugation using Lymphoprep (Nycomed, Oslo, Norway). After
washing in RPMI media and seeding into tissue culture
plates at 105 cells per well, appropriate dilutions of fusion
protein or rIL-2 were added. Following incubation (36 h,
37°C, 5% C02), 0.5 tCi of 3H-thymidine was added to each
well, and after 4 h further incubation cells were harvested
and incorporated radioactivity was measured.
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Results
Expression andaffinity chromatography ofSCA-IL-2/7protein
SCA-IL-2/7 protein expression was induced by addition of
0.1 mM IPTG to transformed cultures of E.coli K12 KS476.
Figure 2a shows a Western Blot of material affinity-purified
from culture growth medium detected with the anti-IL-2
antibody DMS1; this reveals a single band with an apparent
molecular weight of 46kDa. When probed with anti-SCA
serum, a 46 kDa band was still apparent, but a number of
degradation products were revealed (Figure 2b). As DMS1
binds the carboxyl end of IL-2 and does not recognise any of
the degradation products we assume that proteolysis has
removed at least the terminal carboxyl section of the fusion
protein in these degradation products.
The ability of SCA-IL-2/7 fusion protein to bind lysozyme
is demonstrated in Figure 3, where affinity purified material
was allowed to bind immobilised lysozyme and was detected
with polyclonal anti-IL-2. Furthermore, against the panel of
immobilised protein antigens tested in Figure 4 there is no
evidence of the non-specific stickiness sometimes associated
with antibody fragments.
In Elisas (Figure 5) in which SCA-IL-2/7 or rIL-2 are
immobilised on the polyclonal anti-IL-2, the dose response
curves generated with DMS1 are similar for both the fusion
protein and rIL-2. An estimate of the serological activity of
the IL-2 activity of the SCA-IL-2 sample used in these
experiments is 1200-1500 U ml-'.
FACS analysis
FACS analysis was used to determine if the SCA-IL-2 pro-
tein is able to interact with the IL-2 receptors of lymphoid
cells as an intact protein rather than a degraded form consist-
ing of its two parent molecules. Cell surface bound SCA
epitopes can only be demonstrated in the presence of SCA-
IL-2 fusion protein (Figure 6). The fusion protein gives a
b
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Figure 2 Western blot analysis of fusion protein. a, Proteins recognised by antibody DMS-1. Lane A; molecular weight markers;
lane B, rIL-2, and lane C, affinity-purified SCA-IL-2/7. b, Proteins recognised by anti-SCA. Lane D molecular weight markers; lane
E, native SCA, and lane F, affinity-purified SCA-IL-2/7.SCA-IL-2 FUSION PROTEIN 307
0.5
0.4
0.3
0.2
0.1
SCA-IL-2/7
Culture supernatants 1:2
Figure 3 Detection of SCA-IL-2/7 protein by ELISA. Bacterial
culture supematants of cells transformed with pSWsFVDI.3myc
encoding anti-lysozyme single chain antibody (SCA), pSCA-IL-2/
7 encoding Single chain antibody IL-2 fusion protein and pUCl9
were diluted 1:2 and applied to microtitre plates previously
coated with hen egg lysozyme. Bound IL-2 epitopes were detected
using anti-IL-2.
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significant rise in fluorescence compared with the negative
control, whilst free SCA either alone or with free rIL-2 give
no increase on the background value. The specificity of the
fusion protein interaction with the cells is demonstrated by
the reduction of fluorescence almost to background levels in
the presence of excess free rIL-2/ This competitive inhibition
of SCA-IL-2 binding by free rIL-2 demonstrates that the
fusion protein binds to the cells through specific receptor-
ligand interactions. Competition with an excess of a non-
specific protein (TNF) had no effect on the level of SCA-IL-2
binding (Data not shown).
Results from sequential Elisas and western blots also
indicate that the fusion protein is stable under the conditions
of the biological assays described (Data not shown).
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Figure 4 Binding ofpSCA-IL-2/7 culture supernatant to a panel
of protein antigens. Bound proteins were recognised with goat
anti-IL-2 sera.
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Figure 5 Quantitation of the full length IL-2 epitopes as
detected by mAb DMSI in rIL-2 and SCA-IL-2/7 immobilised on
polyclonal anti-IL-2.
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Figure 6 Facs analysis of interactions of SCA-IL-2 fusion protein and CTLL-2 cells, by detection of cell surface bound SCA
epitopes.
F/M/Idpom
PUC 19308 P. SAVAGE et al.
Stimulation ofCTLL-2 cells andperipheral blood lymphocytes
(PBLs) by SCA-IL-2/7protein
In the conditions employed, half-maximal stimulation ofIL-2
dependent CTLL-2 cells occurred at a concentration of ap-
proximately 0.4 U ml-' rIL-2 (Figure 7). SCA-IL-2/7 protein
gave a similar maximal stimulation and dose response curve.
The fusion protein sample achieved a similar half-maximal
stimulation at a 5120 fold dilution, giving activity of the
affinity purified material of approximately 1500 U ml-' rIL-2
against cells bearing the high affinity IL-2 receptor. This
figure is in close agreement with the estimate derived from
the serological assay. Goat anti-rIL-2 sera inhibited the pro-
liferative effects of both rIL-2 and SCA-IL-2/7 protein in a
similar manner, giving complete inhibition at 25 mg ml-'
(Figure 8).
The effects of rIL-2 and SCA-IL-2/7 protein on peripheral
blood lymphocytes, that bear the low and intermediate affinity
forms of the IL-2 receptor, are shown in Figure 9. The dose
response curve illustrates that SCA-IL-2 protein acted in a
similar manner to IL-2 and the activity ofthe affinity purified
material corresponds to approximately 1600 U ml-' rIL-2,
again in close agreement with previous estimates. Native
D1.3 SCA prepared by identical methods had no prolifer-
ative action in either assay (Data not shown).
Discussion
In this study we report the construction, expression and
characterisation of a novel fusion protein, SCA-IL-2/7, that
retains both the antigen binding characteristics of the parent
single chain antibody and the immuno-stimulatory actions of
IL-2. The genetic construct encodes the pelB leader sequence
(Lei et al., 1987) that directs the expressed protein to the
bacterial periplasm, where the oxidising environment should
permit the formation of intramolecular disulphide bonds.
Whilst the majority of material produced by the bacteria was
degraded by proteases to give a product similar to the native
SCA, a significant quantity of functional material was
obtained from the culture supernatant and partially purified
by affinity chromatography. The yield from the current
system is very low, but it is apparent from experience with
similar Fv fragments that yields can be optimised to produce
a many fold improvement (Better et al., 1990).
We have demonstrated that the fusion protein retains anti-
gen binding ability and that it is able to stimulate lymphoid
cells bearing IL-2 receptors. When tested by serological and
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biological assays the fusion protein and IL-2 gave similar
dose response curves: incorporation of IL-2 into this fusion
protein appears not to reduce its activity as it has in a
previously described Fab'IL-2 fusion (Fell et al., 1991). It
may be that the smaller SCA-IL-2 protein permits efficient
receptor complex internalisation. This fusion protein interacts
with and stimulates cells bearing either high or low affinity
IL-2 receptors. The dual specificity may be allowed by the
relatively long linker between the antibody domains and the
IL-2 moiety allowing the amino-terminal end of IL-2 free-
dom to interact with the low affinity receptor. Work with
diptheria toxin-IL-2 fusion proteins has demonstrated the
importance of this mobility in allowing this interaction to
occur effectively (Williams et al., 1987; Kiyokawa et al.,
1991).
We have demonstrated that the SCA-IL-2 protein is stable
under the conditions of the purification and assay and the
FACS results demonstrate that it is intact when it interacts
with the IL-2 receptor on the CTLL-2 cell's surface. In
addition, work in progress demonstrates that the fusion pro-
tein, like IL-2, is able to cause an increase in vascular
permeability (Savage et al., 1993). Although IL-2 induced
permeability on a systemic scale can lead to toxicity (Lotze et
al., 1986), as a localised event it can enhance the passage of
itself and other therapeutic macromolecules into the tumour
and ease access for effector cells (LeBerthon et al., 1991;
Hennigan et al., 1991).
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Figure 8 Inhibition of stimulatory effects of rIL-2 and SCA-IL-
2/7 by polyclonal anti-IL-2 sera.
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Figure 7 Stimulatory effects of rIL-2 and SCA-IL-2/7 fusion protein on high affinity IL-2 receptor-bearing CTLL-2 cells.
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Figure 9 Stimulatory effects of rIL-2 and SCA-IL-2/7 fusion protein on human PBLs, measured by incorporation of 3H-
thymidine.
Our aim is to target, via antibody variable domains, IL-2
activity to cells of the immune system in the area of the
tumour. Accumulation of IL-2 around any inappropriately
targeted normal cells should result in little cytolytic action,
since effector cells do not interact significantly with normal
cells. This approach should therefore much reduce the re-
quirement for highly selective tumour associated antigens.
This contrasts with the potentially detrimental effects of
radionucleide- or toxin-conjugated antibodies binding normal
cells. Whilst the specificity of the current fusion protein is
only suitable for preliminary in vitro experiments, recent
advances in in vitro selection of antibody variable regions
should allow the rapid generation of SCA directed against
appropriate cellular targets.
Encouraging pre-clinical results with rIL-2 have only been
partially supported by clinical experience. Poor clinical re-
sponses are in part owing to failure to achieve long lasting
therapeutic concentrations in target tissues and also the
systemic toxicity associated with large doses. Targeting of
IL-2 by an antibody-derived fusion protein should allow
concentration and prolonged action of rIL-2 within the area
of the tumour whilst minimising systemic toxicity. Since the
SCA-IL-2 described here may interact the low affinity IL-2
receptors on resting PBLs it is unlikely that it will localise
effectively following intra-venous administration. However
regional or direct intra-tumoural administration may result in
accumulation, prolonged residence and an increased anti-
tumour immune response in the tumour. For IV administra-
tion and localisation it will be preferable to have a form that
interacts only with the high affinity IL-2 receptor, as ex-
pressed on NK cells and activated T-cells. Work is in pro-
gress to determine if shortening the linker in the SCA-IL-2
construct will produce a protein that will selectively stimulate
cells bearing the high affinity receptor. SCA-IL-2 fusion pro-
teins may provide an effective method of targeting thera-
peutic doses of rIL-2 to tumours or other targeted cells whilst
significantly reducing systemic toxicity.
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